PBGENE LLY2
Alternative Names: PBGENE-LIVER; PBGENE-LLY2Latest Information Update: 05 Aug 2024
At a glance
- Originator Precision Biosciences
- Class Endoribonucleases; Gene therapies; Hepatoprotectants; Nucleic acids
- Mechanism of Action Gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Liver disorders
Most Recent Events
- 05 Aug 2024 Preclinical trials in Liver disorders in USA (Parenteral), prior to August 2024 (Precision BioScience pipeline, August 2024)
- 09 Sep 2021 Precision BioSciences has patent protection for ARCUS® platform worldwide including USA before September 2021 (Precision BioScience website, September 2021)
- 09 Sep 2021 Early research in Liver disorders in USA (Parenteral) before September 2021